Navigating next-generation HR+/HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression
Translational Breast Cancer Research · 2023-10 · 4 · 31-31
DOI: 10.21037/tbcr-23-41 ↗Kurz gefasst
Editorial in der Zeitschrift Translational Breast Cancer Research, 2023-10. Verfasst von Patrick Neven und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, KU Leuven-University of Leuven, Leuven, Belgium. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, KU Leuven-University of Leuven, Leuven, Belgium.
- Department of Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium.
- Master Student of Medicine, KU Leuven-University of Leuven, Leuven, Belgium.
- Laboratory of Experimental Oncology, University Hospitals Leuven, Leuven, Belgium.
Zitieren
APA
Neven, P., Dullens, L., Han, S., Deblander, A., Van Herck, Y., Van Houdt, M., & Wildiers, H. (2023). Navigating next-generation HR+/HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression. Translational Breast Cancer Research, 4, 31-31. https://doi.org/10.21037/tbcr-23-41
Vancouver
Neven P, Dullens L, Han S, Deblander A, Van Herck Y, Van Houdt M, et al. Navigating next-generation HR+/HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression. Translational Breast Cancer Research. 2023;4:31-31. doi:10.21037/tbcr-23-41
BibTeX
@article{Neven2023,
author = {Neven, Patrick and Dullens, Lieke and Han, Sileny and Deblander, Anne and Van Herck, Yannick and Van Houdt, Maxime and Wildiers, Hans},
title = {Navigating next-generation HR+/HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression},
journal = {Translational Breast Cancer Research},
year = {2023},
volume = {4},
pages = {31--31},
doi = {10.21037/tbcr-23-41}
}
EUVIMED